Table 1.
Characteristics of the study population according to experience of the primary end-point*.
|
All patients
(n = 273) |
Patients with MACEs
(n = 41) |
Patients without MACEs
(n = 232) |
p | |
|---|---|---|---|---|
| Clinical data | ||||
| Male sex | 181 (66%) | 28 (68%) | 153 (66%) | 0.460 |
| Age, yrs | 51 [41; 60] | 46 [35; 69] | 51 [41; 60] | 0.110 |
| NYHA Class III/IV | 64 (23%) | 22 (54%) | 42 (18%) | <0.0001 |
| Atrial fibrillation | 25 (8%) | 9 (22%) | 16 (6%) | 0.002 |
| LBBB, ECG | 55 (21%) | 7 (17%) | 48 (21%) | 0.360 |
| LV Hypertrophy, ECG | 70 (26%) | 9 (22%) | 61 (27%) | 0.327 |
| Comorbility | ||||
| Hypertension | 95 (35%) | 13 (32%) | 82 (25%) | 0.397 |
| Diabetes/IGT | 43 (16%) | 7 (17%) | 36 (16%) | 0.477 |
| Familial cardiomiopathy | 55 (20%) | 11 (27%) | 44 (19%) | 0.174 |
| Alcohol abuse | 23 (8%) | 1 (2%) | 22 (10%) | 0.109 |
| Chronic renal failure | 20 (7%) | 5 (12%) | 15 (7%) | 0.163 |
| Laboratory data | ||||
| BUN, mg/dL | 30 [18; 41] | 33 [21; 40] | 28 [17; 41] | 0.459 |
| Serum creatinine, mg/dL | 0.95 [0.8; 1.12] |
0.97 [0.76; 1.19] |
0.95 [0.8; 1.1] |
0.559 |
| Hb, g/dL | 13.8 [12.7; 14.9] |
13.8 [12.7; 14.5] |
13.9 [12.7; 15] |
0.392 |
| Therapy | ||||
| β-blockers | 250 (92%) | 37 (90%) | 213 (92%) | 0.465 |
| ACEi/ARBs/ARNi | 252 (92%) | 38 (93%) | 214 (92%) | 0.610 |
| MRA | 129 (47%) | 27 (66%) | 102 (44%) | 0.008 |
Values are median [IQR] for continuous variable or n (%) in binary variables.
ACEi, angiotensin converter enzyme inhibitors; ARBs, angiotensin receptor blockers; ARNi, Angiotensin Receptor Neprilysin Inhibitor; BUN, blood urea nitrogen; GLS, global longitudinal strain; IGT, impaired glucose tolerance; LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricle ejection fraction; MACEs, major cardiovascular events; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; RV, right ventricle; RVEF, right ventricle ejection fraction.
Missing values: BUN 28%, Serum creatinine 12%, Hb 14%. No-missing values for other parameters.
MACEs were considered as the study primary outcome measure and were defined as a composite of: (a) cardiovascular death, (b) cardiac transplant or destination therapy ventricular assist device for end-stage heart failure (HF), (c) hospitalization for life-threatening ventricular arrhythmias or implanted cardioverter defibrillator appropriate intervention on sustained ventricular tachycardia >185 beats per minute or ventricular fibrillation.
Bold values correspond to significative p of interaction (p-value < 0.05).